ENZC Enzolytics Inc.
- 0.003500
- -0.000140-3.85%
Enzolytics Inc. News
ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD
Board Appoints Officers ALLEN, Texas, March 25, 2024 /PRNewswire/ -- Enzolytics, Inc. (OTC PINK:ENZC) (" Enzolytics, Inc. (the "Company") On March 19th, 2024, a Special Meeting of the Shareholders o
Enzolytics Announces The Signing Of The Business Combination Agreement With Sagaliam Acquisition Corp
Enzolytics, Inc. (OTC:ENZC) (Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), t
Biogenysis Inc. Announces a Collaboration With Khalpey AI Lab in Using Artificial Intelligence...
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (Enzolytics, Inc. ("ENZC" or the "Company") filed a Supplemental Information report today to provide additional deta
SPAC Sagaliam, Enzolytics Agree to Raise Price of Unit Sale to $450M
Sagaliam Acquisition Corp. Announces Amendment to Non-Binding Term Sheet With Enzolytics Inc. and Addition of New Board Members
NEW YORK, NY / ACCESSWIRE / June 30, 2023 / Sagaliam Acquisition Corp. (NASDAQ:"SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it has amended the executed non-bind
Enzolytics Inc. Continues Progress With Business Combination; Biogenysis Announces Team and Plans for Success
COLLEGE STATION, TX / ACCESSWIRE / April 27, 2023 / Enzolytics, Inc. (OTC PINK:"ENZC" or the "Company") announces its continuing progress with the recently announced business combination between Enzol
Enzolytics Inc. (OTCMKTS:ENZC) Short Interest Down 63.3% in March
Enzolytics Inc. (OTCMKTS:ENZC – Get Rating) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 2,306,400 shares, a drop of 63.3% fro
Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 Anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study
COLLEGE STATION, TX / ACCESSWIRE / October 5, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). The Company announces the completion of the first phase of the animal toxicology studie
Twist Biosciences Collaborates With Enzolytics on Monoclonal Antibodies for Viruses
Enzolytics (OTCPK:ENZC) will work with Abveris, a division of Twist Bioscience (NASDAQ:TWST), on the discovery of monoclonal antibodies against several viruses. The initial focus is on antibodies targ
Enzolytics Inc. Announces Collaboration With Abveris to Discover Monoclonal Antibodies
COLLEGE STATION, TX / ACCESSWIRE / September 16, 2022 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company").Enzolytics, Inc. announces a collaboration with Abveris, a division of Twist Bioscience C
Enzolytics Says Court Dismissed Shareholder Lawsuit Against Company
Enzolytics, Inc. (OTCPK:ENZC), a drug developer focused on infectious diseases, announced Wednesday that a federal judge in Delaware dismissed a lawsuit filed by one of its shareholders requiring the
Enzolytics Inc. Announces Litigation Success, Accounting Progress and Removal of "Yield" Sign on OTC Markets Stock Quotes
COLLEGE STATION, TX / ACCESSWIRE / September 14, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) or the "Company" announces the successful conclusion, in a Delaware Federal litigation, 21-CV-01163-RGA, brough
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). In the first Official Action on the Company's International Patent Application covering i
Enzolytics IPF Immune(TM) Introduced to Large and Small Retail Buyers at Recent ECRM "Weight Management, Nutrition, and Vitamin Program"
COLLEGE STATION, TX / ACCESSWIRE / April 11, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (Large and small retail buyers were introduced to Enzolytics IPF Immune™, an immune modulator that debuted at ECRM'
Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses
COLLEGE STATION, TX / ACCESSWIRE / March 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (In submissions under the Patent Cooperation Treaty (PCT), Enzolytics, Inc. has pending international patent applic
Enzolytics, Inc. Highlights the Introduction of IPF Immune(TM) as CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements
COLLEGE STATION, TX / ACCESSWIRE / March 23, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (80 Percent of Americans Now Use Nutritional Supplements; Interest in Immunity Protection IncreasesEighty-percent o
Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions
COLLEGE STATION, TX / ACCESSWIRE / March 14, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ( Enzolytics' ("ENZC") wholly-owned subsidiary Virogentics, Inc. (the "Subsidiary") today announced its progress to
Enzolytics plans U.S. launch of its nutritional supplement this month
On Thursday, Enzolytics (OTCPK:ENZC +2.5%), a drug development company focused on anti-viral proteins, unveiled plans to launch its immune modulator, Enzolytics IPF Immune, in the U.S. later this mont
Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market This Month
COLLEGE STATION, TX / ACCESSWIRE / March 10, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ( announces that Enzolytics IPF Immune™, its immune modulator, will be introduced into the U.S. market later this m
Analysis
Price Target
No Data
